Table 1.
Pan-antivirals targeting RLRs.
| Pan-antivirals | Formula | Target pathway | Reference |
|---|---|---|---|
| Nucleotide-based | |||
| SB9200 |  |
RLR and NLR | (50–52) |
| RNA-based | |||
| 5′ppp RNA derived from the 5′ and 3′ UTRs of the negative-strand RNA virus Vesicular Stomatitis Virus | GACGAAGACC ACAAAACCAG AUAAAAAAUA AAAUUUAAUG AUAAUAAUGG UUUGUUUGUC UUCGUC |
RLR | (53, 54) |
| 5′ppp RNA (M8) | GACGAAGACCACAAAACCAGAUAAAAAAAAAAAAAAAAAAAAAAAAAAUAAU UUUUUUUUUUUUUUUUUUUUUUUUUUAUCUGGUUUUGUGGUCUUCGUC |
RLR | (55) |
| 5′OH RNA with kink (CBS-13-BPS) | GGUAGACGAAACCAGAUAUAAUAUCUGGUUUCGUUUGCC | RIG-I, ISG56 | (56) |
| 5′PPP SLR | Stem loop RNA with the length of 10 and 14 base pair (GGACGUACGUUUC GACGUACGUCC) and (GGAUCGAUCGAUCGUUCGCGAUCGAUCGAUCC) |
RIG-I | (57) |
| Small molecular compounds | |||
| KIN 100 |  |
IRF 3 | (58) |
| KIN101 |  |
IRF3 | (58) |
| KIN 1000 |  |
IRF 3 | (59) |
| KIN1400 |  |
IRF 3 | (59) |
| KIN1408 |  |
IRF3 | (59) |
| KIN1409 |  |
IRF3 | (59) |
RLRs, RIG-I-like receptors.